EBI-005: Phase III started

Eleven began the double-blind, placebo-controlled, U.S. Phase III OASIS trial to evaluate 5 mg/mL topical EBI-005 thrice daily for 12 weeks in about 650 patients with moderate to severe dry eye disea...